Initial development of HER2-targeted monoclonal antibodies (trastuzumab and pertuzumab) and older pan-HER tyrosine kinase inhibitors (TKIs), such as afatinib, did not yield promising antitumor activity in NSCLC patients with HER2 alterations. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.